Olmutinib Terminated Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02485652Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung